Comments to FDA: Security Requirements for PSE, Ephedrine, and PPA

Share page:

Letter | Oct 22, 2004

Docket Number:
DEA-211P

This letter is submitted on behalf of CHPA, FMI, HDMA, and NACDS. The purpose of the letter is to express our united concern that the DEA’s proposed rule is not supported by existing evidence and will impose a significant burden on the regulated industry.

Related Posts

Press Releases and Statements

CHPA Welcomes Three Consumer Healthcare Industry Members

Press Releases and Statements

CHPA Statement: OTC Pain Relievers and COVID-19 Vaccines